Compare CARG & CRNX Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | CARG | CRNX |
|---|---|---|
| Founded | 2005 | 2008 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | EDP Services | Biotechnology: Pharmaceutical Preparations |
| Sector | Technology | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 3.3B | 3.9B |
| IPO Year | 2017 | 2018 |
| Metric | CARG | CRNX |
|---|---|---|
| Price | $29.92 | $38.45 |
| Analyst Decision | Buy | Strong Buy |
| Analyst Count | 11 | 8 |
| Target Price | $38.32 | ★ $76.75 |
| AVG Volume (30 Days) | 989.7K | ★ 1.3M |
| Earning Date | 05-07-2026 | 05-07-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | ★ 675.00 | N/A |
| EPS | ★ 0.34 | N/A |
| Revenue | ★ $316,861,000.00 | $1,039,000.00 |
| Revenue This Year | $13.89 | $720.10 |
| Revenue Next Year | $8.91 | $184.67 |
| P/E Ratio | $91.59 | ★ N/A |
| Revenue Growth | ★ 59.92 | N/A |
| 52 Week Low | $26.39 | $25.83 |
| 52 Week High | $39.42 | $57.99 |
| Indicator | CARG | CRNX |
|---|---|---|
| Relative Strength Index (RSI) | 26.28 | 47.31 |
| Support Level | $28.80 | $33.19 |
| Resistance Level | $36.22 | $43.71 |
| Average True Range (ATR) | 1.34 | 2.30 |
| MACD | -0.94 | -0.28 |
| Stochastic Oscillator | 0.24 | 31.68 |
CarGurus Inc is a company that acts as an online automotive marketplace connecting buyers and sellers of new and used cars. It provides three types of marketplace Listing products, Restricted Listings, and Enhanced or Featured Listings, through which it offers real-time and historical data analyzing the connections and pricing analysis. The listing platforms offer auto manufacturers and others to buy advertising on the company's site and target consumers based on the make, model, and zip code of the cars. The company operates through two segments, namely U.S. Marketplace and Digital Wholesale. It generates maximum revenue from the U.S. Marketplace segment. Geographically, the company derives its key revenue from the United States and the rest from international markets.
Crinetics Pharmaceuticals Inc is a commercial-stage pharmaceutical company focused on the discovery, development, and commercialization of novel therapeutics for rare endocrine diseases and endocrine-related tumors. Its main product, Palsonify (paltusotine), is a once-daily, oral treatment approved by the FDA for adults with acromegaly who have had an inadequate response to surgery and/or for whom surgery is not an option. Additionally, the company's development pipeline includes several programs, including a late-stage investigational candidate, atumelnant, currently in development for CAH and ADCS, and CRN09682, a NDC candidate that is being developed to treat SST2-expressing NETs and other SST2-expressing solid tumors.